AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Claims:

1. **(Withdrawn)** A composition comprising a liposome or lipid complex and an entrapped active platinum compound, the liposome or lipid complex containing one or more lipids, wherein the active platinum compound to lipid ratio is from 1:50 to 1:2 by weight.

2. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:5 by weight.

3. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:10 by weight.

4. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound is cisplatin.

5. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:25 to 1:15 by weight.

6. **(Withdrawn)** The composition of claim 5, wherein the active platinum compound is cisplatin.

7. **(Withdrawn)** The composition of claim 6, the one or more lipids comprise DPPC.

8. **(Withdrawn)** The composition of claim 7, the one or more lipids comprise cholesterol.

9. **(Withdrawn)** The composition of claim 7, the one or more lipids comprise 50-100 **[90?]** mol% DPPC and 0-50 mol% cholesterol.

10. **(Withdrawn)** The composition of claim 7, the one or more lipids comprise 50-65 mol% DPPC and 35-50 mol% cholesterol.

11. **(Currently amended)** A process for making a platinum aggregate comprising the steps of:

(a) combining an active platinum compound and a hydrophobic matrix carrying system;

(b) establishing the mixture at a first temperature; and

(c) thereafter establishing the mixture at a second temperature, which second temperature is cooler than the first temperature;

wherein the steps (b) and (c) are effective to increase the encapsulation of active platinum compound, wherein steps (b) and (c) are repeated for a total of two or more cycles.

12. **(Canceled)**.

13. **(Original)** The process of claim 11, wherein the active platinum compound solution is produced by dissolving active platinum compound in a saline solution to form a platinum solution.

14. **(Original)** The process of claim 13, wherein the active platinum compound is cisplatin

15. **(Original)** The process of claim 11, wherein the hydrophobic matrix carrying system comprises liposome or lipid complex-forming lipids.

16. **(Original)** The process of claim 15, wherein the one or more lipids comprise DPPC.

17. **(Original)** The process of claim 15, wherein the one or more lipids further comprise cholesterol.

18. (**Original**) The process of claim 11, wherein the hydrophobic matrix carrying system is produced by dissolving one or more lipids in ethanol to form a lipid solution and injecting the lipid solution into an aqueous medium containing active platinum compound.

19. (**Original**) The process of claim 11, further comprising sequentially repeating the steps (b) and (c) for a total of three or more cycles.

20. (**Original**) The process of claim 19, wherein the step (c) comprises establishing the mixture at a temperature from -25 degrees Celsius to 25 degrees Celsius.

21. (**Original**) The process of claim 19, wherein step (c) comprises establishing the mixture at a temperature from -5 degree Celsius to 5 degrees Celsius.

22. (**Original**) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 4 degrees Celsius to 75 degrees Celsius.

23. (**Original**) The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 45 degrees Celsius to 55 degrees Celsius.

24. (**Original**) The process of claim 11, wherein the temperature differential between steps (b) and (c) is 25 degrees Celsius or more.

25. (**Original**) The process of claim 24, wherein the temperature established in step (b) is 50 degrees Celsius or more.

26. (**Original**) The process of claim 11, wherein the temperature established in step (b) is 50 degrees Celsius or more.

27. (**Original**) A platinum aggregate produced by the method of claim 11.

28. (**Original**) A platinum aggregate produced by the method of claim 14.

29. (**Withdrawn**) A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier or diluent.

30. (**Withdrawn**) A pharmaceutical formulation comprising the composition of claim 1, adapted for inhalation by a patient.

31. (**Withdrawn**) A pharmaceutical formulation comprising the composition of claim 1, adapted for injection into a patient.

32. (**Original**) The process of claim 11, further comprising, after all of steps (b) and steps (c) have been completed:

(d) removing un-entrapped active platinum compound by filtering through a membrane having a molecular weight cut-off selected to retain desired liposomes or lipid complexes and adding a liposome or lipid complex compatible liquid to wash out un-entrapped active platinum compound.